表紙
市場調査レポート

TaiMed Biologics Inc. の製品パイプライン分析

TaiMed Biologics Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 293998
出版日 ページ情報 英文 27 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
TaiMed Biologics Inc. の製品パイプライン分析 TaiMed Biologics Inc. - Product Pipeline Review - 2015
出版日: 2015年11月18日 ページ情報: 英文 27 Pages
概要

TaiMed Biologics Inc. は台湾に本社をおくバイオテクノロジー企業で、ウイルス性感染症の予防および治療のための新規医薬品を創薬・開発し、流通に携わっています。パイプライン製品にはAIDSウイルス侵入阻害剤であるTMB-355や、インフルエンザウイルス・ノイラミニダーゼを阻害する低分子治療薬のTMB-571などがあります。

当レポートでは、TaiMed Biologics Inc. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

TaiMed Biologics Inc. の基本情報

  • TaiMed Biologics Inc. の概要
  • 主要情報
  • 企業情報

TaiMed Biologics Inc. :R&Dの概要

  • 主な治療範囲

TaiMed Biologics Inc. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

TaiMed Biologics Inc. :パイプライン製品の概況

  • 臨床段階のパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

TaiMed Biologics Inc. :薬剤プロファイル

  • ibalizumab
  • Drugs to Inhibit Integrase for HIV
  • ibalizumab second generation
  • TMB-571
  • TMB-607
  • TMB-657

TaiMed Biologics Inc. :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

TaiMed Biologics Inc. :最新のパイプライン情報

TaiMed Biologics Inc. :現在休止中のプロジェクト

TaiMed Biologics Inc. :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07759CDB

Summary

Global Markets Direct's, 'TaiMed Biologics Inc. - Product Pipeline Review - 2015', provides an overview of the TaiMed Biologics Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of TaiMed Biologics Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of TaiMed Biologics Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of TaiMed Biologics Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the TaiMed Biologics Inc.'s pipeline products

Reasons to buy

  • Evaluate TaiMed Biologics Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of TaiMed Biologics Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the TaiMed Biologics Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of TaiMed Biologics Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of TaiMed Biologics Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of TaiMed Biologics Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • TaiMed Biologics Inc. Snapshot
    • TaiMed Biologics Inc. Overview
    • Key Information
    • Key Facts
  • TaiMed Biologics Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • TaiMed Biologics Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • TaiMed Biologics Inc. - Pipeline Products Glance
    • TaiMed Biologics Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • TaiMed Biologics Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • TaiMed Biologics Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • TaiMed Biologics Inc. - Drug Profiles
    • ibalizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Integrase for HIV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TMB-571
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TMB-607
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TMB-657
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • TaiMed Biologics Inc. - Pipeline Analysis
    • TaiMed Biologics Inc. - Pipeline Products by Target
    • TaiMed Biologics Inc. - Pipeline Products by Route of Administration
    • TaiMed Biologics Inc. - Pipeline Products by Molecule Type
    • TaiMed Biologics Inc. - Pipeline Products by Mechanism of Action
  • TaiMed Biologics Inc. - Recent Pipeline Updates
  • TaiMed Biologics Inc. - Dormant Projects
  • TaiMed Biologics Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • TaiMed Biologics Inc., Key Information
  • TaiMed Biologics Inc., Key Facts
  • TaiMed Biologics Inc. - Pipeline by Indication, 2015
  • TaiMed Biologics Inc. - Pipeline by Stage of Development, 2015
  • TaiMed Biologics Inc. - Monotherapy Products in Pipeline, 2015
  • TaiMed Biologics Inc. - Phase III, 2015
  • TaiMed Biologics Inc. - Phase I, 2015
  • TaiMed Biologics Inc. - Preclinical, 2015
  • TaiMed Biologics Inc. - Pipeline by Target, 2015
  • TaiMed Biologics Inc. - Pipeline by Route of Administration, 2015
  • TaiMed Biologics Inc. - Pipeline by Molecule Type, 2015
  • TaiMed Biologics Inc. - Pipeline Products by Mechanism of Action, 2015
  • TaiMed Biologics Inc. - Recent Pipeline Updates, 2015
  • TaiMed Biologics Inc. - Dormant Developmental Projects,2015

List of Figures

  • TaiMed Biologics Inc. - Pipeline by Top 10 Indication, 2015
  • TaiMed Biologics Inc. - Pipeline by Stage of Development, 2015
  • TaiMed Biologics Inc. - Monotherapy Products in Pipeline, 2015
  • TaiMed Biologics Inc. - Pipeline by Top 10 Target, 2015
  • TaiMed Biologics Inc. - Pipeline by Top 10 Route of Administration, 2015
  • TaiMed Biologics Inc. - Pipeline by Top 10 Molecule Type, 2015
  • TaiMed Biologics Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top